2023
Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetiteOne-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis.
Munoz Mendoza J, Aponte-Becerra L, Torres C, Rozas J, Francois P, Salcedo J, Barreto A, Rodriguez J, Suarez M, Fornoni A, Contreras G. One-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis. Clinical Nephrology 2023, 99: 51-57. PMID: 36519940, DOI: 10.5414/cn110823.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseCOVID-19 infectionLong-term mortality riskHospital mortalityMortality riskRenal diseaseOdds ratioCOVID-19Higher long-term mortality riskRetrospective chart reviewAdjusted odds ratioLogistic regression modelsESRD patientsCause mortalitySecondary outcomesChart reviewPrimary outcomeHospitalized patientsHigher oddsMortality ratePatientsMortalityOne-yearInfectionSignificant differences
2022
MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial
Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V, Buss S, Fortier C, Khan F, Aponte Becerra L, Ngo L. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. Journal Of Neurology 2022, 269: 4817-4835. PMID: 35482079, PMCID: PMC9046533, DOI: 10.1007/s00415-022-11119-6.Peer-Reviewed Original ResearchConceptsIntranasal insulinCerebral blood flowPlasma insulinBlood flowType 2 diabetes mellitusVerbal memorySerious adverse eventsDouble-blinded trialRandomized clinical trialsType 2 diabetesAge-related functional declineHOMA-IRAdverse eventsDiabetes mellitusPrimary outcomeWeeks treatmentHypoglycemic episodesT2DM participantsControl placeboPreliminary safetyClinical trialsFunctional declineLong-term effectsBackgroundThis studyBetter executive function
2021
193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial
NOVAK V, MANTZOROS C, NOVAK P, MCGLINCHEY R, DAI W, LIOUTAS V, BUSS S, FORTIER C, KHAN F, BECERRA L, NGO L. 193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial. Diabetes 2021, 70 DOI: 10.2337/db21-193-or.Peer-Reviewed Original ResearchIntranasal insulinSpouse/partnerT2DM-related cognitive impairmentType 2 diabetes mellitusPhase 2 trialSignificant adverse eventsRisk of dementiaDual-task walkingNovo NordiskPseudo-continuous arterial spin labelingArterial spin labelingWorld Health OrganizationAdvisory PanelAdverse eventsDiabetes mellitusPrimary outcomeDual taskT2DM participantsKidney diseaseBlind trialControl trialDrug AdministrationType 2Cognitive impairmentT2DM719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study
BECERRA L, KHAN F, NGO L, NOVAK V, MANTZOROS C, GAVRIELI A, UPADHYAY J. 719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study. Diabetes 2021, 70 DOI: 10.2337/db21-719-p.Peer-Reviewed Original ResearchType 2 diabetesSecondary outcomesSpouse/partnerCaloric intakeFood intakeAnthropometric measuresBody compositionIntranasal insulin administrationBody composition outcomesType 2 Diabetes StudyWeeks of treatmentNovo NordiskWorld Health OrganizationAdvisory PanelPrimary outcomeIntervention visitsInsulin resistanceKidney diseaseDiabetes StudyInsulin administrationBody fatBlind trialAnimal studiesComposition outcomesDrug Administration